Processa Pharmaceuticals, Inc.
PCSAProcessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer (NGC) therapies by modifying existing, widely-used oncology drugs to improve their safety-efficacy profiles.
Earnings
Next report
Nov 2, 2026 (Today)Competitors
By market cap
By revenue growth
By net margin
Profile
Processa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer (NGC) therapies by modifying existing, widely-used oncology drugs to improve their safety-efficacy profiles. The company utilizes a proprietary Regulatory Science Approach to optimize dosage regimens and reduce toxicity, aiming to mitigate clinical and regulatory risks while accelerating commercial adoption. Additionally, the company maintains a non-oncology pipeline and an operating digital asset treasury strategy to diversify its capital base.
Processa differentiates itself through its proprietary Regulatory Science Approach and alignment with the FDA's Project Optimus initiative to optimize drug dosing.
FAQ
- What is Processa Pharmaceuticals, Inc.'s market cap?
- Processa Pharmaceuticals, Inc. (PCSA) has a market capitalization of $5.3M and trades on NASDAQ.
- Who are Processa Pharmaceuticals, Inc.'s competitors?
- Processa Pharmaceuticals, Inc.'s key competitors include Pfizer Inc., CNS Pharmaceuticals, Inc. Common Stock, PharmaCyte Biotech, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Processa Pharmaceuticals, Inc. partner with?
- Processa Pharmaceuticals, Inc.'s notable partners include Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and others.
- Where is Processa Pharmaceuticals, Inc. headquartered?
- Processa Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2013.